Amivantamab plus Lazertinib in Previously Untreated <i>EGFR</i> -Mutated Advanced NSCLC
Byoung Chul Cho, Shun Lu, Enriqueta Felip, Alexander I. Spira, Nicolas Girard, Jong-Seok Lee, Se-Hoon Lee, Yurii Ostapenko, Pongwut Danchaivijitr, Baogang Liu, Adlinda Alip, Ernesto Korbenfeld, Josiane Mourão Dias, Benjamin Besse, Ki-Hyeong Lee, Hailin Xiong, Soon-Hin How, Ying Cheng, Gee‐Chen Chang, Hiroshige Yoshioka, James Chih‐Hsin Yang, Michael J. Thomas, Danny Nguyen, Sai‐Hong Ignatius Ou, Sanjay Mukhedkar, Kumar Prabhash, M. D’Arcangelo, Jorge Alatorre-Alexander, Juan Carlos Vázquez Limón, Sara Alves, Daniil Stroyakovskiy, Marina Peregudova, Mehmet Alı Nahıt Şendur, Ozan Yazıcı, Raffaele Califano, Vanesa Gutiérrez Calderón, Filippo de Marinis, Antonio Passaro, Sang‐We Kim, Shirish M. Gadgeel, John Xie, Tao Sun, Melissa Martínez, Mariah Ennis, E. Fennema, Mahesh Daksh, Dawn Millington, Isabelle Leconte, Ryota Iwasawa, Patricia Lorenzini, Mahadi Baig, Sujay Shah, Joshua Bauml, S. Martin Shreeve, Seema Sethi, R.E. Knoblauch, Hidetoshi Hayashi
Abstract
BACKGROUND: (epidermal growth factor receptor)-mutated advanced non-small-cell lung cancer (NSCLC). METHODS: -mutated (exon 19 deletion or L858R), locally advanced or metastatic NSCLC to receive amivantamab-lazertinib (in an open-label fashion), osimertinib (in a blinded fashion), or lazertinib (in a blinded fashion, to assess the contribution of treatment components). The primary end point was progression-free survival in the amivantamab-lazertinib group as compared with the osimertinib group, as assessed by blinded independent central review. RESULTS: -related toxic effects. The incidence of discontinuation of all agents due to treatment-related adverse events was 10% with amivantamab-lazertinib and 3% with osimertinib. CONCLUSIONS: -mutated advanced NSCLC. (Funded by Janssen Research and Development; MARIPOSA ClinicalTrials.gov number, NCT04487080.).